Cancer Research
Intervention Study for Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Oregovomab Plus Chemo in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma Following Optimal Debulking Surgery
AGE: >18 years old
GENDER: Female
GENDER: Female
CONDITION: Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Peritoneal Carcinoma
TYPE: Drug study
HEALTHY PARTICIPANTS: No
HEALTHY PARTICIPANTS: No
Learn More About This Research Study
For more information, please contact Lauren Patrick at 216-844-8724 or complete the online form below.
Study Purpose
The purpose of this study is to see how safe and effective four doses of the experimental study drug oregovomab is when given through a vein in your arm at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.
Who Can Participate
Participants 18 years and older diagnosed with epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin may be eligible for this study.